Dilution of hyaluronidase: concentration and purpose
Why the reconstitution of hyaluronidase differs between elective dissolution and vascular emergency, and why no reliable units-per-millilitre-of-filler conversion exists.
Hyaluronidase is supplied as a lyophilised powder and must be reconstituted before use. The choice of diluent volume is not a detail of preparation: it determines both the concentration of enzyme delivered and the volume of tissue that can be reached, and those two variables serve different purposes in different clinical situations.
Two variables, two purposes
Reconstituting a 1500-unit vial into a small volume produces a concentrated solution suitable for delivering enzyme activity to a defined target. Reconstituting the same vial into a larger volume produces a dilute solution that distributes further through tissue for the same total dose. Total units and volume are independent choices, and confusing them is the most common error in discussions of hyaluronidase dosing.
Concentration governs the rate at which the enzyme degrades hyaluronic acid it contacts. Volume governs how much tissue the solution physically reaches. A high-unit dose delivered in a tiny volume treats a small area intensely; the same dose in a larger volume treats a wider field less intensely.
Elective dissolution
Elective dissolution — correcting a nodule, an overfilled area, a Tyndall-affected tear trough — is a targeted problem. The material to be dissolved is palpable or visible and its location is known. The published approach is conservative: modest unit doses, placed into or immediately around the deposit, with review at an interval that allows the effect to be assessed before repeating. Overshoot in this setting is not harmless, because hyaluronidase also acts on native hyaluronic acid in the surrounding tissue.
Because the target is identifiable, dilution here is usually chosen to keep volume small enough that the solution stays where it is placed rather than spreading into untargeted tissue.
Emergency use in vascular occlusion
Vascular occlusion inverts every one of those assumptions. The obstructing material is inside a vessel, its exact location is unknown, and the objective is not to correct an aesthetic result but to restore perfusion to an ischaemic territory before tissue is lost. Time is the dominant variable.
The published high-dose pulsed protocols are built around flooding the affected vascular territory rather than treating a point. A frequently quoted working concentration in this literature is a 1500-unit vial reconstituted in approximately 1 mL, which is then delivered across the ischaemic area and repeated in pulses at intervals of roughly one hour until capillary refill, colour and pain improve. Systematic review of high-dose pulsed use for impending necrosis, and individual reports of intervention beyond the traditionally cited window, both describe repeated dosing continued according to clinical response rather than to a predetermined ceiling.
The reasoning behind flooding is anatomical. The enzyme has to reach intravascular filler through the vessel wall or via collateral flow, the precise course of the occluded branch is not known at the bedside, and the safe assumption is that the whole territory supplied by the implicated artery may contain obstructed material.
Why there is no conversion factor
Practitioners frequently look for a figure of the form “x units dissolves y mL of filler”. No such figure is reliable, for several reasons.
Degradation rate depends on the specific product: cross-linking density, gel concentration and particle characteristics all alter susceptibility, and in vitro comparisons show substantial differences between commercially available fillers. It depends on contact — enzyme that does not reach the gel does nothing, and a cohesive bolus presents far less surface area per millilitre than the same volume distributed through tissue. It depends on time in situ, on local perfusion carrying enzyme away, and on the individual’s own hyaluronidase activity.
The practical consequence is that dosing in both settings is titrated to observed clinical effect and reassessed, not calculated from the volume of filler believed to be present. Documentation of what was used, at what concentration, and at what times is part of that process rather than an administrative afterthought.
